title: [Bayesian prediction of chloramphenicol blood levels in children with sepsis and malnutrition].
abstract: OBJECTIVE
  To validate the population pharmacokinetic parameters of chloramphenicol in pediatric patients with sepsis and malnutrition (PPSM) using a bayesian forecasting program.
  
  
  METHODS
  Retrospective evaluation of predictive performance of a bayesian program in PPSM.
  
  
  METHODS
  Tertiary care center.
  
  
  METHODS
  Fifteen MPSP and ten NMPSP that receiving treatment with chloramphenicol.
  
  
  RESULTS
  In the first part of the study, the medical records of 10 MPSP and 10 NMPSP who had received treatment with chloramphenicol were reviewed. The population pharmacokinetic parameter values for each group were estimated using a nonparametric expectation maximization algorithm (NPEM). In the second part, data gathered from five other MPSP receiving chloramphenicol were entered into a bayesian program. Chloramphenicol pharmacokinetic values for each of these five patients were estimated, first using the values of NMPSP as a priori distribution and then repeating the analysis using the MPSP values. The bayesian serum chloramphenicol concentrations predicted for each population model were compared with the actual peaks and troughs. The specific model for MPSP permitted forecasting the peak and trough serum chloramphenicol concentrations with less bias and a better precision compared with the NMPSP population model.
  
  
  CONCLUSIONS
  These data indicate that chloramphenicol pharmacokinetics in PPSM can be predicted with minimal bias and good precision using a bayesian forecasting program, allowing a better control of the chloramphenicol serum concentrations. In addition, the limited number of samples required by the bayesian method may represent an important economical benefit for the patient.
authors.affiliation: Departamento de Farmacología, Instituto Nacional de Pediatría (INP), Secretaría de Salud (SS), México.
authors.forename: I
authors.initials: I
authors.lastname: Lares-Asseff
authors.forename: G
authors.initials: G
authors.lastname: Lugo-Goytia
authors.forename: M G
authors.initials: MG
authors.lastname: Pérez-Guillé
authors.forename: B
authors.initials: B
authors.lastname: Pérez Ortíz
authors.forename: A
authors.initials: A
authors.lastname: Guillé-Pérez
authors.forename: H
authors.initials: H
authors.lastname: Juárez-Olguín
authors.forename: J
authors.initials: J
authors.lastname: Flores-Pérez
authors.forename: P
authors.initials: P
authors.lastname: Santiago
authors.forename: M
authors.initials: M
authors.lastname: Morlán
mesh_terms: D000900:Anti-Bacterial Agents / Q000097:blood* / Q000493:pharmacokinetics; D001499:Bayes Theorem; D002648:Child; D002701:Chloramphenicol / Q000097:blood* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D009748:Nutrition Disorders / Q000097:blood*; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D018805:Sepsis / Q000097:blood*
chemical_list: D000900:Anti-Bacterial Agents; D002701:Chloramphenicol